Drugs that contain Irinotecan Hydrochloride

1. Drug name - ONIVYDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9782349 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US8992970 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US10722508 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US9724303 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US8329213 IPSEN INC Liposomes useful for drug delivery
Jan, 2027

(4 years from now)

US8147867 IPSEN INC Liposomes useful for drug delivery
Aug, 2028

(5 years from now)

CN107811971B IPSEN INC Liposomes For Drug Delivery
May, 2025

(2 years from now)

CN1980637B IPSEN INC Liposome For Drug Delivery
May, 2025

(2 years from now)

CN1980637A IPSEN INC Lipidosome For Carrying The Medicine
May, 2025

(2 years from now)

CN103948545A IPSEN INC Liposome For Drug Delivery
May, 2025

(2 years from now)

CN107811971A IPSEN INC A Medicine Conveying Liposome
May, 2025

(2 years from now)

CN103948545B IPSEN INC Liposome For Drug Delivery
May, 2025

(2 years from now)

IN201207908P1 IPSEN INC A Fluid Pharmaceutical Formulation
May, 2025

(2 years from now)

IN200607275P1 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

IN361032B IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

IN374803B IPSEN INC A Fluid Pharmaceutical Formulation
May, 2025

(2 years from now)

EP1746976A4 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

EP1746976A1 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

EP1746976B1 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703181 IPSEN INC Liposomes useful for drug delivery May, 2025

(2 years from now)

US9730891 IPSEN INC Liposomes useful for drug delivery May, 2025

(2 years from now)

US9717724 IPSEN INC Methods for treating pancreatic cancer using combination therapies Jun, 2033

(10 years from now)

US9492442 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US9364473 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US9339497 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US9452162 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US10980795 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US10456360 IPSEN INC Stabilizing camptothecin pharmaceutical compositions Oct, 2036

(14 years from now)

US10993914 IPSEN INC Stabilizing camptothecin pharmaceutical compositions Oct, 2036

(14 years from now)

Treatment: Treatment of pancreatic cancer; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient not homozygous for the ugt1a1*28 allele; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele; Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.